NovaScan™, at a glance
Neutralizing antibodies are key biomarkers of protective immunity and play a critical role in vaccine development, immune monitoring, seroprevalence studies, and gene therapy, yet their detection often relies on labor-intensive, slow, and difficult-to-standardize neutralization assays.
NovaScan™ provides a rapid and biologically relevant alternative by reproducing critical virus–cell interactions using engineered virus-like particles and cell-like particles. The platform enables functional detection of neutralizing antibodies without live viruses or cell culture, significantly reducing assay complexity while preserving biological relevance.
Key Benefits
Functional neutralization readout
High reproducibility and standardized workflows
Results in approximately 4 hours
Less than 1 hour of hands-on time
Cell-free and virus-free workflow
Automation-compatible format
Reduced biosafety and operational constraints
Compatible with multiple biological fluids
Discover our platforms
NovaScan™ is currently being developed and validated for several infectious disease applications, including SARS-CoV-2, H5N1 influenza, norovirus, and other emerging viral threats. Beyond infectious diseases, the platform is also being developed for anti-AAV neutralizing antibody detection to support the growing field of AAV gene therapy, where pre-existing immunity remains a major challenge for patient eligibility, vector selection, and therapeutic efficacy.
NovaScan for Infectious Diseases
NovaScan for AAV
Get your document
Fill out the form below to get your document
"*" indicates required fields
